Cargando…

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation

Pancreatic cancer has an abysmal prognosis. Targets for early detection, prevention and therapy are desperately needed. Inflammatory pathways have an important impact on tumour growth and progression. Expression of BLT2 (the second leukotriene B(4) receptor) was investigated by real-time RT–PCR and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hennig, R, Osman, T, Esposito, I, Giese, N, Rao, S M, Ding, X-Z, Tong, W-G, Büchler, M W, Yokomizo, T, Friess, H, Adrian, T E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567081/ https://www.ncbi.nlm.nih.gov/pubmed/18781173 http://dx.doi.org/10.1038/sj.bjc.6604655

Ejemplares similares

Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN
por: Distler, M., et al.
Publicado: (2014)

Branch Duct – IPMN and PanIN, in IgG4‐Autoimmune pancreatitis: A case report
por: Lazzarin, Gianni, et al.
Publicado: (2020)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma
por: McGinnis, Timothy, et al.
Publicado: (2020)

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma
por: Beckermann, B M, et al.
Publicado: (2008)

Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs)
por: Imai, Koji, et al.
Publicado: (2015)

De-regulation of the sonic hedgehog pathway in the InsGas mouse model of gastric carcinogenesis
por: El-Zaatari, M, et al.
Publicado: (2007)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth
por: Li, D, et al.
Publicado: (2014)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized (13)C Metabolic Magnetic Resonance Spectroscopy
por: Dutta, Prasanta, et al.
Publicado: (2020)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

CCL19 reduces tumour burden in a model of advanced lung cancer
por: Hillinger, S, et al.
Publicado: (2006)

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
por: Zhang, X, et al.
Publicado: (2014)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
por: Yen, W-C, et al.
Publicado: (2006)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
por: Hu, X F, et al.
Publicado: (2007)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Sigma-2 ligands induce tumour cell death by multiple signalling pathways
por: Zeng, C, et al.
Publicado: (2012)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_5bbqo3pigppi1lruks06bbpbh9